Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 1002-1017

  Shin, A H ^a   Kim, H J ^b   Thayer, S A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Dankook University   (South Korea)

Author keywords

dizocilpine; HIV Tat; HIV associated neurocognitive disorders (HAND); ifenprodil; memantine; neurotoxicity; NMDA receptor; synapse loss; synapse recovery; TCN201

Indexed keywords

DIZOCILPINE; GREEN FLUORESCENT PROTEIN; IFENPRODIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POSTSYNAPTIC DENSITY PROTEIN 95; PROPIDIUM IODIDE; TCN 201; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL SURVIVAL; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; HIPPOCAMPUS; MOLECULAR IMAGING; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STUDY; RAT; REGULATORY MECHANISM; SYNAPSE; SYNAPTIC TRANSMISSION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CULTURE MEDIA; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MEMANTINE; MICROSCOPY, CONFOCAL; NEURONS; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SULFONAMIDES; SYNAPSES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 84860868793     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01805.x     Document Type: Article

References (62)

1. Arnold DB, Clapham DE, (1999). Molecular determinants for subcellular localization of PSD-95 with an interacting K+ channel. Neuron 23: 149-157.
2. Avenet P, Leonardon J, Besnard F, Graham D, Frost J, Depoortere H, et al,. (1996). Antagonist properties of the sterioisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopos oocytes. Eur J Pharmacol 296: 209-213.
3. Bettini E, Sava A, Griffante C, Carignani C, Buson A, Capelli AM, et al,. (2010). Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J Pharmacol Exp Ther 335: 636-644.
4. Black M, Lanthorn T, Small D, Mealing G, Lam V, Morley P, (1996). Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur J Pharmacol 317: 377-381.
5. Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schettini G, (2001). HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons. Biochem Biophys Res Commun 288: 301-308.
6. Boyce-Rustay JM, Holmes A, (2006). Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31: 2405-2414.
7. Bruce-Keller AJ, Chauhan A, Dimayuga FO, Gee J, Keller JN, Nath A, (2003). Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci 23: 8417-8422.
8. Chen HSV, Lipton SA, (1997). Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol 499: 27-46.
9. Christopherson KS, Hillier BJ, Lim WA, Bredt DS, (1999). PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274: 27467-27473.
10. Coan EJ, Saywood W, Collingridge GL, (1987). MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampals slices. Neurosci Lett 80: 111-114.
11. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg LK, et al,. (2003). Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 40: 595-607.
12. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, et al,. (2005). Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25: 8375-8385.
13. Ellis R, Langford D, Masliah E, (2007). HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8: 33-44.
14. Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, Bennett MV, et al,. (2007). HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A 104: 3438-3443.
15. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al,. (1999). Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9: 209-217.
16. Fitting S, Xu R, Bull C, Buch S, El-Hage N, Nath A, et al,. (2010). Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177: 1397-1410.
17. Foster AC, Wong EHF, (1987). The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 91: 403-409.
18. Gambrill AC, Barria A, (2011). NMDA receptor subunit composition controls synaptogenesis and synapse stabilization. Proc Natl Acad Sci U S A 108: 5855-5860.
19. Ge Y, Dong Z, Bagot RC, Howland JG, Phillips AG, Wong TP, et al,. (2010). Hippocampal long-term depression is required for the consolidation of spatial memory. Proc Natl Acad Sci U S A 107: 16697-16702.
20. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, et al,. (1992). Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176: 1703-1718.
21. Gill R, Foster AC, Woodruff G, (1987). Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 7: 3343-3349.
22. Hardingham GE, Fukunaga Y, Bading H, (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414.
23. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, et al,. (2000). Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 6: 145-155.
24. Huettner JE, Bean BP, (1988). Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A 85: 1307-1311.
25. Hult B, Chana G, Masliah E, Everall I, (2008). Neurobiology of HIV. Int Rev Psychiatry 20: 3-13.
26. Kaul M, Lipton SA, (2006). Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4: 307-318.
27. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ, (2003). Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162: 1693-1707.
28. Kim HJ, Thayer SA, (2009). Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides. Mol Pharmacol 75: 1021-1030.
29. Kim HJ, Martemyanov KA, Thayer SA, (2008). Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 28: 12604-12613.
30. Kim HJ, Shin AH, Thayer SA, (2011). Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. Mol Pharmacol 80: 357-366.
31. King JE, Eugenin EA, Buckner CM, Berman JW, (2006). HIV tat and neurotoxicity. Microbes Infect 8: 1347-1357.
32. Kruman II, Nath A, Mattson MP, (1998). HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154: 276-288.
33. Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, et al,. (2006). Lithium improves HIV-associated neurocognitive impairment. AIDS 20: 1885-1888.
34. Li ST, Matsushita M, Moriwaki A, Saheki Y, Lu YF, Tomizawa K, et al,. (2004). HIV-1 Tat inhibits long-term potentiation and attenuates spatial learning. Ann Neurol 55: 362-371.
35. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, et al,. (2004). Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity. Science 304: 1021-1024.
36. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, et al,. (2000). Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 6: 1380-1387.
37. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, et al,. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27: 2846-2857.
38. Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U, (2008). A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18: 125-134.
39. Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE, et al,. (2003). Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 117: 43-53.
40. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, et al,. (1997). Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 42: 963-972.
41. Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, et al,. (2004). Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24: 7821-7828.
42. McArthur JC, (2004). HIV dementia: an evolving disease. J Neuroimmunol 157: 3-10.
43. Minagar A, Commins D, Alexander JS, Hoque R, Chiappelli F, Singer EJ, et al,. (2008). NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. Mol Diagn Ther 12: 25-43.
44. Muir KW, Lees KR, (1995). Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513.
45. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, et al,. (2003). Glycine binding primes NMDA receptor internalization. Nature 422: 302-307.
46. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D, (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337-1350.
47. Pasti L, Zonta M, Pozzan T, Vicini S, Carmignoto G, (2001). Cytosolic calcium oscillations in astrocytes may regulate exocytotic release of glutamate. J Neurosci 21: 477-484.
48. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
49. Roche KW, Standley S, McCallum J, Ly CD, Ehlers MD, Wenthold RJ, (2001). Molecular determinants of NMDA receptor internalization. Nat Neurosci 4: 794-802.
50. Rusakov DA, Kullmann DM, (1998). Extrasynaptic glutamate diffusion in the hippocampus-ultrastructural constraints, uptake, and receptor activation. J Neurosci 18: 3158-3170.
51. Sa MJ, Madeira MD, Ruela C, Volk B, Mota-Miranda A, Paula-Barbosa MM, (2004). Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. Acta Neuropathol 107: 97-110.
52. Shen M, Thayer SA, (1998). The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res 783: 77-84.
53. Shi Y, Ethell IM, (2006). Integrins control dendritic spine plasticity in hippocampal neurons through NMDA receptor and Ca2+/calmodulin-dependent protein kinase II-mediated actin reorganization. J Neurosci 26: 1813-1822.
54. Speth C, Stockl G, Mohsenipour I, Wurzner R, Stoiber H, Lass-Florl C, et al,. (2001). Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol 75: 2604-2615.
55. Tovar KR, Westbrook GL, (1999). The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19: 4180-4188.
56. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, et al,. (2005). Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 21: 706-713.
57. Waataja JJ, Kim HJ, Roloff AM, Thayer SA, (2008). Excitotoxic loss of post-synaptic sites is distinct temporally and mechanistically from neuronal death. J Neurochem 104: 364-375.
58. Wiley CA, Baldwin M, Achim CL, (1996). Expression of regulatory and structural mRNA in the central nervous system. AIDS 10: 943-947.
59. Wiley CA, Masliah E, Achim CL, (1999). Measurement of CNS HIV burden and its association with neurologic damage. Adv Neuroimmunol 4: 319-325.
60. Williams K, (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor-selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44: 851-859.
61. Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iverson LL, (1986). The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83: 7104-7108.
62. Xia P, Chen HSV, Zhang D, Lipton SA, (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30: 11246-11250.